A PYMNTS Company

Israel: Teva in talks to buy Allergan’s generics unit for $45 billion

By  |  July 26, 2015

Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC’s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva’s pursuit of another acquisition.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday.

    Teva has been seeking to buy Mylan NV, a deal Mylan has been resisting as it pursues fellow drug maker Perrigo Co. PLC.

    The merger would be the latest to shake up a major sector of the health-care industry, and come on the heels of two big announcements in which four of the largest managed-care companies— Anthem Inc. and Cigna Corp. and Aetna Inc. and Humana Inc.—agreed to combine into two companies, in deals worth a combined $82 billion.

    Full content: The Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.